Erik Sveberg Dietrichs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erik Sveberg Dietrichs has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Torkjel Tveita
Norwegian Air Ambulance Foundation, Research and Development Department, Oslo, Norway
7 shared publications- Torkjel Tveita
Anesthesia and Critical Care Research Group, Faculty of Health Sciences, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway
7 shared publications Georg Sager
Experimental and Clinical Pharmacology, Department of Medical Biology, UiT - the Arctic University of Norway, Tromsø, Norway
5 shared publicationsGodfrey Smith
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland
5 shared publications- Timofei Kondratiev
Anesthesia and Critical Care Research Group, Department of Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromsø, Norway
5 shared publications Anders Lund Selli
Experimental and Clinical Pharmacology, Department of Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway, Langnes, Tromsø, Norway
4 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Association between clozapine-induced hypertriglyceridemia and defenestration of liver sinusoidal endothelial cells
Clozapine is the most effective antipsychotic drug, while also causing the most severe metabolic side effects. The underlying mechanisms of these side effects appear multifactorial and are not entirely understood. We hypothesized that liver sinusoidal endothelial cells (LSEC) dysfunction is linked to the metabolic side effects of clozapine, based on known association between reduced LSEC porosity, hypertriglyceridemia and insulin resistance. Accordingly, we conducted a translational study by assessing the porosity of murine LSECs following clozapine exposure in vitro and correlating serum clozapine concentrations with metabolic parameters in routine human blood samples. The patient data showed a correlation for clozapine serum concentrations with both triglycerides (Spearman’s ρ = 0.47, P = 0.00024) and glucose levels (ρ = 0.24, P = 0.034), but no correlation with LDL cholesterol (ρ = −0.04, P = 0.82) or HDL cholesterol (ρ = −0.22, P = 0.088). The in vitro experiments showed a concentration-dependent reduction in murine LSEC porosity (P for trend = 0.00036). Together, these findings support a link between clozapine exposure and reduced LSEC porosity. This represents a promising point of intervention that potentially could expand safe access to clozapine as a highly effective antipsychotic treatment for a broader population, also in individuals at high risk for metabolic and cardiovascular side effects.
- 6 August 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessAssociation between clozapine-induced hypertriglyceridemia and defenestration of liver sinusoidal endothelial cells
Clozapine is the most effective antipsychotic drug, while also causing the most severe metabolic side effects. The underlying mechanisms of these side effects appear multifactorial and are not entirely understood. We hypothesized that liver sinusoidal endothelial cells (LSEC) dysfunction is linked to the metabolic side effects of clozapine, based on known association between reduced LSEC porosity, hypertriglyceridemia and insulin resistance. Accordingly, we conducted a translational study by assessing the porosity of murine LSECs following clozapine exposure in vitro and correlating serum clozapine concentrations with metabolic parameters in routine human blood samples. The patient data showed a correlation for clozapine serum concentrations with both triglycerides (Spearman’s ρ = 0.47, P = 0.00024) and glucose levels (ρ = 0.24, P = 0.034), but no correlation with LDL cholesterol (ρ = −0.04, P = 0.82) or HDL cholesterol (ρ = −0.22, P = 0.088). The in vitro experiments showed a concentration-dependent reduction in murine LSEC porosity (P for trend = 0.00036). Together, these findings support a link between clozapine exposure and reduced LSEC porosity. This represents a promising point of intervention that potentially could expand safe access to clozapine as a highly effective antipsychotic treatment for a broader population, also in individuals at high risk for metabolic and cardiovascular side effects.
- Open Access
- 25 October 2023
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 31 (1) , 1-16
Proarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro study
Background: Accidental hypothermia, recognized by core temperature below 35 °C, is a lethal condition with a mortality rate up to 25%. Hypothermia-induced cardiac dysfunction causing increased total peripheral resistance and reduced cardiac output contributes to the high mortality rate in this patient group. Recent studies, in vivo and in vitro, have suggested levosimendan, milrinone and isoprenaline as inotropic treatment strategies in this patient group. However, these drugs may pose increased risk of ventricular arrhythmias during hypothermia. Our aim was therefore to describe the effects of levosimendan, milrinone and isoprenaline on the action potential in human cardiomyocytes during hypothermia. Methods: Using an experimental in vitro-design, levosimendan, milrinone and isoprenaline were incubated with iCell2 hiPSC-derived cardiomyocytes and cellular action potential waveforms and contraction were recorded from monolayers of cultured cells. Experiments were conducted at temperatures from 37 °C down to 26 °C. One-way repeated measures ANOVA was performed to evaluate differences from baseline recordings and one-way ANOVA was performed to evaluate differences between drugs, untreated control and between drug concentrations at the specific temperatures. Results: Milrinone and isoprenaline both significantly increases action potential triangulation during hypothermia, and thereby the risk of ventricular arrhythmias. Levosimendan, however, does not increase triangulation and the contractile properties also remain preserved during hypothermia down to 26 °C. Conclusions: Levosimendan remains a promising candidate drug for inotropic treatment of hypothermic patients as it possesses ability to treat hypothermia-induced cardiac dysfunction and no increased risk of ventricular arrhythmias is detected. Milrinone and isoprenaline, on the other hand, appears more dangerous in the hypothermic setting.
- 25 October 2023
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 31 (1) , 1-16
Open AccessProarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro study
Background: Accidental hypothermia, recognized by core temperature below 35 °C, is a lethal condition with a mortality rate up to 25%. Hypothermia-induced cardiac dysfunction causing increased total peripheral resistance and reduced cardiac output contributes to the high mortality rate in this patient group. Recent studies, in vivo and in vitro, have suggested levosimendan, milrinone and isoprenaline as inotropic treatment strategies in this patient group. However, these drugs may pose increased risk of ventricular arrhythmias during hypothermia. Our aim was therefore to describe the effects of levosimendan, milrinone and isoprenaline on the action potential in human cardiomyocytes during hypothermia. Methods: Using an experimental in vitro-design, levosimendan, milrinone and isoprenaline were incubated with iCell2 hiPSC-derived cardiomyocytes and cellular action potential waveforms and contraction were recorded from monolayers of cultured cells. Experiments were conducted at temperatures from 37 °C down to 26 °C. One-way repeated measures ANOVA was performed to evaluate differences from baseline recordings and one-way ANOVA was performed to evaluate differences between drugs, untreated control and between drug concentrations at the specific temperatures. Results: Milrinone and isoprenaline both significantly increases action potential triangulation during hypothermia, and thereby the risk of ventricular arrhythmias. Levosimendan, however, does not increase triangulation and the contractile properties also remain preserved during hypothermia down to 26 °C. Conclusions: Levosimendan remains a promising candidate drug for inotropic treatment of hypothermic patients as it possesses ability to treat hypothermia-induced cardiac dysfunction and no increased risk of ventricular arrhythmias is detected. Milrinone and isoprenaline, on the other hand, appears more dangerous in the hypothermic setting.
- Open Access
- 23 October 2023
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 143 (15)
Hvordan menneskeskapte klimaendringer påvirker helse
23.10.2023: Kronikk - Klodens gjennomsnittstemperatur ligger mer enn én grad høyere enn den gjorde før den industrielle revolusjonen.
- 23 October 2023
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 143 (15)
Open AccessHvordan menneskeskapte klimaendringer påvirker helse
23.10.2023: Kronikk - Klodens gjennomsnittstemperatur ligger mer enn én grad høyere enn den gjorde før den industrielle revolusjonen.
- Open Access
- 26 August 2023
- Published by Elsevier in EBioMedicine
- Vol. 95, 104779
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
- 26 August 2023
- Published by Elsevier in EBioMedicine
- Vol. 95, 104779
Open AccessPro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
- Open Access
- 14 January 2023
- Published by Elsevier in Cryobiology
- Vol. 110, 18-23
Moderate but not severe hypothermia increases intracellular cyclic AMP through preserved production and reduced elimination
- 14 January 2023
- Published by Elsevier in Cryobiology
- Vol. 110, 18-23
Open AccessModerate but not severe hypothermia increases intracellular cyclic AMP through preserved production and reduced elimination
- Open Access
- 15 December 2022
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 30 (1) , 1-10
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
Background: Rewarming from hypothermia is associated with severe complications, one of which is hypothermia-induced cardiac dysfunction. This condition is characterized by decreased cardiac output accompanied by increased total peripheral resistance. This contributes to mortality rate approaching 40%. Despite this, no pharmacological interventions are recommended for these patients below 30 °C. Raising the intracellular levels of cAMP and/or cGMP, through PDE3- and PDE5-inhibitors respectively, have showed the ability to alleviate hypothermia-induced cardiac dysfunction in vivo. Drugs that raise levels of both cAMP and cGMP could therefore prove beneficial in patients suffering from hypothermia-induced cardiac dysfunction. Methods: The unselective PDE-inhibitor pentoxifylline was investigated to determine its ability to reach the intracellular space, inhibit PDE3 and PDE5 and inhibit cellular efflux of cAMP and cGMP at temperatures 37, 34, 30, 28, 24 and 20 °C. Recombinant human PDE-enzymes and human erythrocytes were used in the experiments. IC50-values were calculated at all temperatures to determine temperature-dependent changes. Results: At 20 °C, the IC50-value for PDE5-mediated enzymatic breakdown of cGMP was significantly increased compared to normothermia (IC50: 39.4 µM ± 10.9 µM vs. 7.70 µM ± 0.265 µM, p-value = 0.011). No other significant changes in IC50-values were observed during hypothermia. Conclusions: This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures. This can potentially be effective treatment of hypothermia-induced cardiac dysfunction. Trial registration: Not applicable.
- 15 December 2022
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 30 (1) , 1-10
Open AccessPharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
Background: Rewarming from hypothermia is associated with severe complications, one of which is hypothermia-induced cardiac dysfunction. This condition is characterized by decreased cardiac output accompanied by increased total peripheral resistance. This contributes to mortality rate approaching 40%. Despite this, no pharmacological interventions are recommended for these patients below 30 °C. Raising the intracellular levels of cAMP and/or cGMP, through PDE3- and PDE5-inhibitors respectively, have showed the ability to alleviate hypothermia-induced cardiac dysfunction in vivo. Drugs that raise levels of both cAMP and cGMP could therefore prove beneficial in patients suffering from hypothermia-induced cardiac dysfunction. Methods: The unselective PDE-inhibitor pentoxifylline was investigated to determine its ability to reach the intracellular space, inhibit PDE3 and PDE5 and inhibit cellular efflux of cAMP and cGMP at temperatures 37, 34, 30, 28, 24 and 20 °C. Recombinant human PDE-enzymes and human erythrocytes were used in the experiments. IC50-values were calculated at all temperatures to determine temperature-dependent changes. Results: At 20 °C, the IC50-value for PDE5-mediated enzymatic breakdown of cGMP was significantly increased compared to normothermia (IC50: 39.4 µM ± 10.9 µM vs. 7.70 µM ± 0.265 µM, p-value = 0.011). No other significant changes in IC50-values were observed during hypothermia. Conclusions: This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures. This can potentially be effective treatment of hypothermia-induced cardiac dysfunction. Trial registration: Not applicable.
- Open Access
- 21 November 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (17)
E.S. Dietrichs og medarbeidere svarer
21.11.2022: Kommentar - I likhet med en kommentar publisert i 2009 av samme forfatter, antydes det her at dosen av antidepressiver i prinsippet ikke er av betydning for den kliniske responsen pasienten opplever (1).
- 21 November 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (17)
Open AccessE.S. Dietrichs og medarbeidere svarer
21.11.2022: Kommentar - I likhet med en kommentar publisert i 2009 av samme forfatter, antydes det her at dosen av antidepressiver i prinsippet ikke er av betydning for den kliniske responsen pasienten opplever (1).
- 7 November 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (16)
E. S. Dietrichs og medarbeidere svarer
07.11.2022: Kommentar - Vi vil takke Morten Svendsen Næss for en relevant kommentar til vår artikkel «Genotyping av pasienter behandlet med selektive serotonin-reopptakshemmere» (1).
- 7 November 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (16)
E. S. Dietrichs og medarbeidere svarer
07.11.2022: Kommentar - Vi vil takke Morten Svendsen Næss for en relevant kommentar til vår artikkel «Genotyping av pasienter behandlet med selektive serotonin-reopptakshemmere» (1).
- 3 October 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (14)
Antidopaminergt syndrom – ikke malignt nevroleptikasyndrom
03.10.2022: Språkspalten - Såkalt malignt nevroleptikasyndrom kan oppstå ved alle former for opphør av dopaminerg stimulering og bør derfor kalles antidopaminergt syndrom.
- 3 October 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (14)
Antidopaminergt syndrom – ikke malignt nevroleptikasyndrom
03.10.2022: Språkspalten - Såkalt malignt nevroleptikasyndrom kan oppstå ved alle former for opphør av dopaminerg stimulering og bør derfor kalles antidopaminergt syndrom.
- 26 September 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (13)
Genotyping of patients treated with selective serotonin reuptake inhibitors
26.09.2022: Originalartikkel - Blant mer enn 3 000 pasienter hadde omtrent hver sjuende pasient en kombinasjon av genotyper av CYP2D6, CYP2C19 og SLC6A4 som anses å gi mest gunstig metabolisme og effekt ved behandling med selektive serotoninreopptakshemmere.
- 26 September 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (13)
Genotyping of patients treated with selective serotonin reuptake inhibitors
26.09.2022: Originalartikkel - Blant mer enn 3 000 pasienter hadde omtrent hver sjuende pasient en kombinasjon av genotyper av CYP2D6, CYP2C19 og SLC6A4 som anses å gi mest gunstig metabolisme og effekt ved behandling med selektive serotoninreopptakshemmere.